IOL Chemicals Q4 FY26 Consolidated PAT at ₹20.58 Cr, Down 54%
IOL Chemicals reported Q4 FY26 consolidated PAT of ₹20.58 Cr, a 54% decrease from ₹44.90 Cr in Q4 FY25. Full-year consolidated PAT was ₹184.44 Cr, down from ₹195.65 Cr. Standalone PAT for Q4 FY26 was ₹27.55 Cr, down from ₹53.18 Cr. Board approved results on May 20, 2026.
The decrease in profits, while significant, does not indicate a severe financial crisis. The company continues to operate and has published its results, suggesting a moderate impact on investor sentiment and stock performance.
The company reported a significant decrease in both quarterly and annual profits (PAT) for both consolidated and standalone results compared to the previous year, indicating a negative financial performance.
IOL Chemicals and Pharmaceuticals Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated total income from operations of ₹621.19 crore for the quarter, a decrease from ₹532.30 crore in the same period last year. For the full year, the consolidated total income stood at ₹2,101.62 crore, down from ₹2,340.34 crore in the previous fiscal year.
The consolidated Profit After Tax (PAT) for the quarter ended March 31, 2026, was ₹20.58 crore, a significant decrease of approximately 54% compared to ₹44.90 crore in the corresponding quarter of the previous year. For the full fiscal year, the consolidated PAT was ₹184.44 crore, down from ₹195.65 crore in FY25.
The standalone results also showed a similar trend. Standalone PAT for the quarter was ₹27.55 crore, down from ₹53.18 crore year-on-year. For the full year, standalone PAT was ₹137.72 crore, a decrease from ₹195.57 crore in FY25.
The Board of Directors approved these financial results on May 20, 2026, following a review by the Audit Committee. The detailed financial results are available on the company's website and the stock exchange websites.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.